Summary Previous investigators have noted that certain ovarian cancer cell lines secrete and respond to transforming growth factor-a (TGF-a), suggesting that endogenous activation of the epidermal growth factor (EGF) receptor through autocrine or paracrine mechanisms might contribute to the proliferative response. In order to determine whether autocrine stimulation was partly responsible for the proliferative response in ovarian cancer, we investigated whether the EGF receptor expressed by ovarian cancer cell lines was constitutively activated as assessed by the presence of tyrosine phosphorylation. A specific antiphosphotyrosine antibody was used in conjunction with an immunoblotting technique in order to detect EGF receptor phosphorylation in ovarian cancer cell lines in the absence and presence of exogenous EGF. The effects of neutralising anti-EGF receptor antibody on the proliferation of ovarian cancer cell lines was also examined. We found no evidence for constitutive tyrosine phosphorylation of the p170 EGF receptor in eight epithelial ovarian cancer cell lines tested, although each line demonstrated inducible phosphorylation in response to exogenous EGF. The absence of constitutive EGF receptor activation was also noted when cells were grown under high density conditions, thus excluding a role for membrane-bound EGF or TGF-a in this process. Media conditioned by five ovarian cancer cell lines, as well as malignant ascites obtained from 12 different ovarian cancer patients, were not capable of stimulating EGF receptor phosphorylation. Finally, the proliferation of ovarian cancer cell lines was not significantly inhibited in the presence of neutralising anti-EGF receptor antibody. These data suggest that EGF receptor activation through autocrine pathways is not a major mechanism for the growth of many ovarian cancer cell lines. Other pathways of signal transduction which bypass the requirement for EGF receptor activation may be important in the proliferation for ovarian cancer cells. Such EGF receptor-independent pathways may limit the effectiveness of strategies designed to inhibit ovarian cancer cell growth through disruption of EGF receptor function.
Epithelial ovarian cancer is a highly lethal disease which spreads extensively throughout the abdominal cavity. Factors which predict for poor outcome include advanced stage, older age, high tumour grade, amplification of the c-neu protooncogene and overexpression of the epidermal growth factor (EGF) receptor (Slamon et al., 1989; Berchuck et al., 1991; Scambia et al., 1992; Cannistra, 1993) . The association between EGF receptor expression and poor prognosis has raised the possibility that this receptor may be involved in the proliferative response of ovarian cancer cells in vivo through autocrine or paracrine mechanisms. In this regard, many ovarian cancer cell lines as well as cells from fresh ovarian tumours respond to exogenous EGF in vitro, and some ovarian cancer cell lines express mRNA and protein for transforming growth factor-alpha (TGF-a), a known ligand for the EGF receptor Crew et al., 1992; Stromberg et al., 1992; Zhou and Leung, 1992; Morishige et al., 1993) . Some investigators have also shown that neutralising anti-TGF-a antibody is capable of partly inhibiting proliferation of certain ovarian cancer cells lines in vitro, suggesting involvement of TGF-alpha and the EGF receptor in an autocrine loop (Stromberg et al., 1992; Morishige et al., 1993) .
The EGF receptor is widely expressed on several types of epithelial cells, including the normal ovarian surface epithelium (NOSE) which gives rise to most cases of ovarian cancer (Bast et al., 1992) . This receptor is a membrane tyrosine kinase which characteristically forms homodimers after ligand binding to either EGF or TGF-oa (Ullrich and Schlessinger, 1990) . Homodimerisation results in stimulation of tyrosine kinase activity and autophosphorylation of several tyrosine moieties contained within the receptor's cytoplasmic domain. Since tyrosine phosphorylation is critical to EGF receptor function, detection of phosphorylated tyrosine moieties provides an accurate assessment of this receptor's activation state (Carpenter and Cohen et al., 1990; Ullrich and Schlessinger, 1990) .
The expression of EGF receptors by ovarian cancer cells and the ability of these cells to respond to EGF in vitro provides only circumstantial evidence that this signal transduction pathway is involved in the proliferative response. Therefore, the purpose of this study was to define more accurately the activation status of the EGF receptor in ovarian cancer cells by performing immunoblotting with a specific anti-phosphotyrosine antibody. Our results demonstrate that the EGF receptor is not constitutively activated in many ovarian cancer cell lines, and that the proliferation of ovarian cancer cells is not significantly inhibited in the presence of neutralising anti-EGF receptor antibody. The implications of these observations for ovarian cancer pathogenesis are discussed.
Materials and methods Reagents
Immunoblotting was performed using a previously described murine anti-phosphotyrosine (P-Tyr) monoclonal antibody (MAb) developed by one of us (BD). This antibody is specific for phosphotyrosine, as demonstrated by complete elimination of immunoreactive bands with the addition of used for inhibition of cell line proliferation was purchased from Oncogene Science (Uniondale, NY, USA chloride, 330 jg ml-' nitro blue tetrazolium (NBT) and 150 jug ml-1 5-bromo-4-chloro-3-indolyl phosphate (BICP) for 10-30 min. The enzymatic colour reaction was stopped by rinsing the filters in deionised water.
Immunoprecipitation
For some experiments, immunoprecipitation of the EGF receptor was performed before immunoblot analysis. Briefly, 7.5 x 106 cells were suspended in 1 ml lysis buffer for 30 min at 40C. After lysis, the solubilised fraction was obtained by centrifugation (14 000 r.p.m. x 30 min) to remove insoluble debris, followed by preclearing with 50 ul of a 1:1 slurry of lysis buffer and Protein A-Sepharose beads (type CL-4B, Pharmacia, Piscataway, NJ, USA) precoated with polyclonal rabbit anti-mouse immunoglobulin (RaM Ig, Dako). After centrifugation, the precleared supernatant was incubated with either an isotype-identical irrelevant antibody (DI44) or with anti-EGF receptor antibody and rabbit anti-mouse Ig-coated Protein A-Sepharose beads for 15 h at 40C, followed by pelleting and washing three times in lysis buffer. The immunoprecipitate was boiled for 5 min at 100°C in nonreducing conditions and analysed by SDS-PAGE, followed by protein transfer and immunoblot analysis as described above.
Proliferation assay
The effects of EGF or anti-EGF-R antibody on the proliferation of ovarian cancer cell lines were assessed by measuring the cleavage of MTT (diemthylthiazol-diphenyl tetrazolium bromide, Sigma) to formazan as previously described (Mosmann, 1983) . Briefly, cells (2.5 x 103 per well) were added in quadruplicate to 96-well microtitre plates in a total volume of 100 jl of IMDMEM containing 10% FCS and allowed to incubate at 37°C for a total of 120 h. During the last 4 h of incubation, 10 jl of MTT (5 mg ml-' in PBS) was added, followed by the addition of 100 jl of 0.04 N hydrochloric acid in isopropanol to dissolve the formazan. After mixing, the optical density of each well was measured on an ELISA plate reader at a wavelength of 590 nm. Control cultures included incubation of cells in anti-CD44 antibody (clone 515), which is an IgGI murine monoclonal antibody which binds to the ovarian cancer cells used in this study but does not significantly affect their proliferation . Specific optical density (OD) was defined as the OD of the treatment group containing cells minus the OD of wells containing media without cells. Data were expressed as the stimulation index, which is a ratio of the specific OD of the treatment group divided by the specific OD of cells grown in the presence of control antibody (anti-CD44 antibody).
Statistical analysis Data are expressed as mean+standard error of the mean (s.e.m.) where appropriate. Significance levels for comparison of stimulation indices between treatment groups were determined using the two-sided Student's t-test for unpaired samples.
Results
Status of EGF receptor tyrosine phosphorylation in ovarian cancer cell lines In order to assess the phosphorylation status of the EGF receptor in ovarian cancer cell lines, we performed immunoblotting of a variety of cell lysates using a murine anti-phosphotyrosine antibody. In pilot studies using the CAOV-3 line, we have shown that this technique is capable of detecting inducible phosphorylation of the p170 kDa EGF receptor in the presence of >0.5 ng ml-1 EGF after a 10 min exposure at 37°C, with maximum phosphorylation observed C Ottensmeier et a! 448 at a dose of 10 ng ml-' EGF. 
Identification of p1 70 as the EGF receptor
In order to confirm that pl70 was identical to the EGF receptor, we first treated CAOV-3 cells with or without EGF as described, followed by immunoprecipitation of cell lysates with an anti-EGF receptor (anti-EGF-R) antibody. Each immunoprecipitate was divided into two equal aliquots which were then separately resolved by SDS-PAGE for subsequent immunoblotting with either anti-EGF-R or anti-phosphotyrosine antibody (Figures 2a and b) . Whole cell lysates were also loaded to serve as a control for the presence of p170. Figure 2a shows the results of immunoblotting with the anti-EGF-R antibody, demonstrating an EGF receptor species at 170 kDa in the whole cell lysate groups (lanes A and D) and in the groups immunoprecipitated with anti-EGF receptor antibody (lanes C and F). As expected, the EGF receptor is not observed in the groups immunoprecipitated with control antibody (anti-D144, lanes B and E). When these same lysates are immunoblotted with anti-phosphotyrosine antibody as shown in Figure 2b , no reactivity is observed for either whole cell lysates or anti-EGF receptor immunoprecipitates of cells treated with media alone (lanes A and C). In contrast, there is strong expression of the p170 phosphotyrosine in both whole cell lysates as well as the EGF receptor immunoprecipitates in the presence of EGF (lanes D and F). These data demonstrate that the p170 band observed in whole cell lysates is identical to the EGF receptor. Effects of anti-EGF receptor neutralising antibody on the proliferation of ovarian cancer cell lines These data suggest that significant levels of constitutive EGF receptor activation are not responsible for the proliferation of the ovarian cancer cell lines used in this study. However, we also considered the possibility that the sensitivity of immunoblot analysis might not be sufficient to exclude definitively an autocrine pathway of EGF receptor activation mediated through EGF or TGF-a secretion. In order to determine whether external activation of the EGF receptor might be partly responsible for the proliferation of ovarian cancer cell lines, we incubated cells in the presence of either EGF or anti-EGF-R antibody for 120 h, followed by assessment of proliferation by the MTT assay as described. As shown in Table I , the A431 squamous cell carcinoma cell line was significantly inhibited by 10 pg ml-' of anti-EGF-R antibody, with a stimulation index of 0.58 compared with control antibody (anti-CD44) (P=0.001). EGF (10 ng ml-') resulted in an inhibitory effect in A431 cells, consistent with the known ability of relatively high concentrations of this factor to induce apoptosis in this cell line (Gulli et al., 1995) . The inhibitory effect of EGF on A431 cells was blocked by anti-EGF-R antibody (10 pg ml-'), thus demonstrating the specificity of this antibody for the EGF receptor (data not Ascites from 12 separate patients with newly diagnosed ovarian cancer was collected in heparin (100 U ml -), followed by centrifugation and collected of the cell-free fraction which was used in these experiments. CAOV-3 cells were exposed to either SFM, EGF (10 ngml-') or to undiluted ascites as indicated for 10min at 37°C. None of the ascites samples was capable of inducing tyrosine phosphorylation of p170 in CAOV-3 cells. Effects of CAOV-3 cell density on EGF receptor tyrosine phosphorylation. CAOV-3 cells were plated at a subconfluent density (0.1 x 106Mml -20% FCS/IMDMEM) and allowed to grow for either 24 or 96 h before immunoblot analysis as described. At 24 h the cells were non-confluent, whereas a confluent monolayer was present at 96h. There was no evidence of constitutive p170 tyrosine phosphorylation under confluent or non-confluent conditions, although phosphorylation was inducible by a 10min exposure to exogenous EGF (lOngml'). The immunoblotting assay used in these experiments was ideally suited to determining the role of constitutive EGF receptor activation in ovarian cancer for several reasons. This assay detected an inducible tyrosine phosphoprotein of 170 kDa which was shown to be specific for the EGF receptor by immunoprecipitation. In addition, p170 was phosphorylated by as little as 0.5 ng ml-' EGF, a concentration which typically produces an absent or low level proliferative response in the ovarian cancer cell lines used in this study (data not shown). It is unlikely, therefore, that biologically significant amounts of EGF receptor ligand present in conditioned medium or ascites would be missed in these experiments. Although it is certainly possible that more sensitive assays of EGF or TGF-ac measurement would reveal the presence of these cytokines in conditioned medium or ascites, the biological significance of these levels in the absence of a significant effect on EGF receptor phosphorylation is difficult to determine. For instance, the use of radioimmunoassay has revealed low level expression of TGF-ax in the range of 0.016-0.197 ng ml-' in many epithelial ovarian cancer cell lines, including OVCAR-3 and SKOV-3 (Stromberg et al., 1992) . The fact that we were unable to detect growth stimulation at these TGF-a (or EGF) concentrations suggests that this level of growth factor secretion may not be relevant to the in vitro proliferation of the ovarian cancer cell lines used in this study. Also, constitutive tyrosine phosphorylation of the EGF receptor in A431 cells was easily detected by immunoblotting ( Figure  lc) , suggesting that this assay should be capable of demonstrating this phenomenon in the other cell lines used in this study. It is important to note, however, that A43 1 cells have been shown to overexpress constitutively phosphorylated EGF receptors dramatically (Gulli et al., 1995) , raising the possibility that the immunoblot assay used in this study may not always be capable of detecting constitutive phosphorylation of lower numbers of receptors typical of ovarian cancer cell lines . Finally, it is known that constitutive activation of EGF receptor function may occur through at least three distinct pathways, including autocrine stimulation of the receptor by secreted ligands present in the extracellular space (Di Marco et al., 1989; Stromberg et al., 1992; Morishige et al., 1993 , autocrine stimulation by non-secreted ligands present in the cytoplasmic compartment (Keating and Williams, 1988) , and upregulation of function owing to EGF receptor truncation (Khazaie et al., 1988) . Since tyrosine phosphorylation is a common feature of each of these pathways, the immunoblotting technique has the additional advantage of allowing the detection of activated EGF receptors regardless of their mechanism of stimulation.
Although all ovarian cancer cell lines used in this study demonstrated inducible tyrosine phosphorylation of the EGF receptor, two of the five lines tested failed to show a proliferative response in the presence of this growth factor (UPN36T) and OVCAR-3). This observation is consistent with the experience of other investigators , who have noted lack of EGF responsiveness despite the presence of adequate EGF receptor surface expression. The fact that EGF receptor activation is not always associated with a proliferative response, coupled with the observation that this receptor is not constitutively phosphorylated, suggests that other pathways of signal transduction may be important in ovarian cancer cell growth. In this regard, it is interesting to note that Mills et al. (1988 Mills et al. ( , 1990 have characterised a soluble growth factor present in the malignant ascites of ovarian cancer patients which is capable of inducing ovarian cancer cell proliferation. This factor appears to be distinct from EGF by its ability to induce increases in intracellular calcium when added to ovarian cancer cells in vitro (Mills et al., 1988) . In addition, several other EGF-independent pathways of signal transduction have been identified, including activation of the c-neu protooncogene, a protein which is capable of inducing malignant transformation in vitro and which is overexpressed in over 20% of ovarian cancer specimens (Di Fiore et al., 1987; Hudziak et al., 1987; Slamon et al., 1989) . Abnormalities of tumour-suppressor proteins such as p53, which is mutated in over 50% of ovarian cancer specimens (Kupryjanczyk et al., 1993; Milner et al., 1993; Teneriello et al., 1993) , may also be a critical component of disordered growth regulation in this disease. It is possible that such EGF receptor-independent pathways may limit the effectiveness of strategies designed to inhibit ovarian cancer cell growth through disruption of EGF receptor function. Although we cannot exclude a possible contributory role of EGF receptor-mediated proliferation in ovarian cancer pathogenesis, our data suggest that constitutive activation of the EGF receptor may not be an important component of the proliferative response in at least some cases of ovarian cancer.
